Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil. - Peixoto de Miranda ÉJF; Calado RT; Boulos FC; de Sousa Moreira JA; Machado FF; Almeida MAALDS; Da Rocha MCO; Infante V; Mercer LD; Hjorth R; Scharf R; White J; et al. (Vaccine, 2025)